Century Therapeutics announces CNTY-813 T1D program; Q3 net loss $34.4M, cash $132.7M

Century Therapeutics, Inc.

CNTY-813 is iPSC-derived beta islet therapy for T1D; preclinical data show reversal of diabetes in mouse models.
IND-enabling studies for CNTY-813 to start by year-end 2025; IND submission planned as early as 2026.
Q3 2025 net loss $34.4M vs $31.2M in Q3 2024; R&D expenses down to $22.5M from $27.2M.
Cash and investments $132.7M as of Sep 30, 2025; estimated cash runway into Q4 2027.
Discontinuing company-sponsored CALiPSO-1 trial; continuing CARAMEL IST with data expected Dec 5, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.